Search Results - Jiro Mukai
- Showing 1 - 1 results of 1
-
1
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19 by Junsaku Kitagawa, Hayato Arai, Hiroyuki Iida, Jiro Mukai, Kenji Furukawa, Seitaro Ohtsu, Susumu Nakade, Tomohiro Hikima, Miwa Haranaka, Naoto Uemura
Published 2021Call Number: Loading…Connect to this object online.
Located: Loading…
Book